Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Share News (N4P)

Share Price Information for N4 Pharma Plc (N4P)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.625
Bid: 0.60
Ask: 0.65
Change: 0.00 (0.00%)
Spread: 0.05 (8.333%)
Open: 0.625
High: 0.625
Low: 0.625
Prev. Close: 0.625
N4P Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: HSBC Rises After Upbeat Third Quarter

Mon, 29th Oct 2018 10:51

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------HSBC, up 4.7%. The Asia-focused bank reported an "encouraging" third quarter with consensus beating profit. For the three months ended September, pretax profit rose 28% to USD5.92 billion from USD4.62 billion the year prior. Excluding the impact of currency translation, pretax profit rose 16% on the year before. Revenue rose 1.6% to USD13.80 billion from USD13.58 billion the year before. Revenue performance was driven by "strong" growth in all of HSBC's three main global businesses. Shore Capital called HSBC's third-quarter results strong, saying adjusted pretax profit of USD6.19 billion, up 16% on year, was 8% better than consensus at USD5.73 billion and 6% better than Shore's own forecast of USD5.86 billion. Group operating expenses decreased 6.8% to USD7.97 billion from USD8.55 billion the year before. This is largely due the bank's significant items decreasing to USD228 million from USD762 million. The large drop in one-off costs included the non-recurrence of "costs to achieve", which had been USD700 million in the year-ago comparative period. ----------Shire, up 2.5%. Japanese drugmaker Takeda Pharmaceutical said it is considering selling an experimental inflammatory bowel disease drug that is under development by its takeover target Shire. Takeda confirmed its discussion with the European Commission regarding potential overlap between its marketed product Entyvio and Shire's pipeline compound SHP647. SHP647 is a human monoclonal antibody that targets mucosal addressin cell adhesion molecule, which is currently undertaking phase III clinical trials. Takeda has proposed a potential divestment of SHP647 and associated rights. Takeda confirmed on Monday that there are no discussions with the European Commission regarding any other marketed products or assets in the pipeline.----------FTSE 100 - LOSERS----------Just Eat, down 5.2%. Peel Hunt downgraded the online takeaway platform to Sell from Buy. The broker said the rise of rivals Uber and Deliveroo could lead to the demise of Just Eat, given the two can outspend the FTSE 100 constituent and outperform in the smartphone space. Bloomberg in September reported that ride-hailing app Uber - which also offers a food delivery service Uber Eats - was in early discussions with Deliveroo, as part of its strategy to invest and partner with rivals ahead of its planned initial public offering next year.----------OTHER MAIN MARKET AND AIM - WINNERS----------N4 Pharma, up 20%. The cancer-focused pharmaceutical company's shares rose after a key research study demonstrated positive results for its Nuvec delivery system. Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin. The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems. As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required. In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.----------Lok'n Store, up 10%. The storage company said its earnings grew in its recently ended financial year following a rise in occupancy and store numbers. Lok'n Store said pretax profit in the year to the end of July improved to GBP5.3 million from GBP4.0 million reported a year earlier, as revenue rose to GBP17.8 million from GBP16.7 million. The company noted the result was driven by occupancy increases in both old and new stores. Tight control over operating costs led to a 2% increase in self-storage margins, which has also contributed in pushing the company's profit to "record level". Lok'nStore declared an annual dividend of 11 pence per share, up 10% from 10p paid the year prior.----------OTHER MAIN MARKET AND AIM - LOSERS----------Warpaint Group, down 43%. The colour cosmetics supplier said the UK market has remained challenging for the company with softening sales, even as it expects a rise in profit and revenue for 2018. Warpaint said its UK market, which accounted for 44% of group's sales in the first half of the year, saw further softening following the end of the interim period due to retailers reducing their stock levels and Christmas orders. The group said the reduction in previously anticipated UK sales will hurt its performance for 2018, which will not be completely offset by an outperformance in its sales territories overseas. As at September 30, sales in the US were up 60% compared to the same period in 2017, and sales in the EU were up 14% year-on-year.----------Gama Aviation, down 17%. The aviation service provider lowered its full-year expectations after trading in some of its divisions has not improved "sufficiently" during the second half of 2018. Gama said it now expects the annual underlying operating profit to be USD3 million below its original expectations. In 2017, Gama generated underlying operating profit of USD18.7 million. On a divisional basis, the company's Air unit saw stable performance in Europe, Middle East & Asia. However, profit from the US is now below Gama's expectations due to slower-than-anticipated growth in charter and aircraft management revenue. In Asia, Gama's associate China Air Services has continued to underperform with the unexpected loss of contracts significantly harming margins. ----------
More News
14 Sep 2020 10:52

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

N4 Pharma Plunges 40% As Covid-19 Antibody Delivery Study Disappoints

Read more
14 Sep 2020 09:04

N4 Pharma plunges as Covid-19 progress stalls

(Sharecast News) - N4 Pharma lost more than a third of its value after the company said its potential Covid-19 vaccine delivery method did not produce a positive result at stage 3 of tests.

Read more
1 Sep 2020 21:35

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

IN BRIEF: N4 Pharma Signs Technology Transfer & Manufacturing Contract

Read more
1 Sep 2020 09:19

N4 Pharma chooses Ardena as contract manufacturing partner

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has appointed the API and nanomedicines business unit of Ardena as its contract development and manufacturing organisation partner for the technology transfer and upscaling manufacture of 'Nuvec', it announced on Tuesday.

Read more
12 Aug 2020 14:18

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

N4 Pharma Shares Spike 30% On Successful Covid-19 Study

Read more
6 Jul 2020 14:13

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

IN BRIEF: N4 Pharma's Nuvec Shows Promise In Oral Vaccine Delivery

Read more
28 May 2020 14:49

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

UK TRADING UPDATE SUMMARY: PureTech, N4, Synairgen Advance Covid Work

Read more
28 May 2020 09:47

N4 Pharma completes first stage proof of concept work for Nuvec

(Sharecast News) - Pharmaceutical group N4 Pharma has completed the first phase of Covid-19 proof of concept work for Nuvec, the group's novel delivery system for cancer treatments and vaccines.

Read more
18 May 2020 15:39

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

N4 Pharma To File Nuvec Patent Across Europe, US, Other Major Markets

Read more
13 May 2020 14:55

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

N4 Pharma Raises GBP2 Million To Fund Covid-19 Research Project

Read more
13 May 2020 11:30

N4 Pharma raises ?2.03m via oversubscribed placing

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has raised ?2.03m through an oversubscribed placing of 50,731,250 new ordinary shares, it announced on Wednesday, at a price of 4p each.

Read more
24 Apr 2020 14:33

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

N4 Pharma Files Patent For Nuvec Opportunities In Viral Vector Market

Read more
24 Apr 2020 09:30

N4 Pharma files for new UK patent on 'Nuvec'

(Sharecast News) - Specialist pharmaceutical company N4 Pharma has filed a new UK patent application around both the ability of its 'Nuvec' delivery system ability to be used to manufacture viral vectors, and to make viral vectors more efficient in applications such as ex-vivo gene therapy treatments.

Read more
16 Apr 2020 15:59

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
16 Apr 2020 14:57

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

UK TRADING UPDATE SUMMARY: NHS Uses Induction Healthcare's Mobile App

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.